Home > Products > API > Eldecalcitol
Eldecalcitol
  • EldecalcitolEldecalcitol

Eldecalcitol

Product Name: Eldecalcitol
Formulae hypotheticae: C30H50O5
M. Pondus; 490,71
CAS Subcriptio Number; 104121-92-8

Model:CAS NO:104121-92-8

Mitte Inquisitionem

depictio producti

Eldecalcitol

Product nomen:Eldecalcitolum 104121-92-8
CAS No:104121-92-8
Specification: in domo

Nomen Eldecalcitol
Synonyma 2-(3-hydroxypropoxy)-1,25-dihydroxyvitaminD3;Eldecalcitolum; -hydroxy-6-methylheptan-2-yl)-7a-methylhexahy dro-1H-inden-4(2H)-ylidene) ethylidene) -2-(3-hydroxypropoxy) -4-methylenecyclohexane-1,3-diol;1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)viChemic albooktaminD3;Eldecalcitolum(ED-71);2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitaMinD3;(1S,2S,3S,5Z)-5-[(2E)-2-[( 1R,3aS,7aR) -1-[(2R)-6-hyd roxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene] ethylidene]-2-(3-hydroxypropoxy)-4- methylidenecyclohexane-1,3-diol
copyRight
M. Structure CAS # 59-02-9, Vitamin E, D-alpha-Tocopherol, (2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
Formulae hypotheticae C30H50O5
M. Pondus 490.71
CAS Subcriptio Number 104121-92-8


Tractantem et repono
Cautiones pro tutum pertractatio
Bene ventilatas tractantem in loco. Apta tutela vestitus. Pelle et oculis contactum fuge. Fuge formationem pulveris et aerosols. Utere instrumentis non-noctis. Ne ignis per electrostatic missionem vaporis.
Conditiones repono pro tuto, inter quaslibet incompatibilitates
Repone continens arcte clausum in loco sicco, frigido et bene ventilato. Disponunt a vasis victualibus vel materiae repugnantibus.

Imprimis usus finis (s): oeconomiae laboratoriae, ad investigationes scientificas et evolutionem tantum



Hot Tags: Eldecalcitolum, China, Suppliers, Manufacturers, Factory
Related Categoria
Mitte Inquisitionem
Libenter placet, ut inquisitionem tuam in forma infra exhibeas. Respondebimus tibi in 24 horis.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept